Titan Pharmaceuticals, Inc. (TTNP) Short Interest Update

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) was the target of a significant growth in short interest in October. As of October 31st, there was short interest totalling 8,743,759 shares, a growth of 479.5% from the October 15th total of 1,508,880 shares. Based on an average daily trading volume, of 28,857,144 shares, the days-to-cover ratio is currently 0.3 days. Currently, 37.0% of the shares of the stock are short sold.

Shares of TTNP stock opened at $0.40 on Friday. Titan Pharmaceuticals has a fifty-two week low of $0.17 and a fifty-two week high of $1.85. The stock has a market cap of $9.12 million, a P/E ratio of -0.57 and a beta of -0.13.

Titan Pharmaceuticals (NASDAQ:TTNP) last announced its earnings results on Tuesday, August 14th. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.09. Titan Pharmaceuticals had a negative return on equity of 1,659.34% and a negative net margin of 295.69%. The business had revenue of $2.67 million during the quarter, compared to analysts’ expectations of $0.07 million. On average, equities analysts forecast that Titan Pharmaceuticals will post -0.42 EPS for the current fiscal year.

In other news, Director James R. Mcnab bought 200,000 shares of the firm’s stock in a transaction that occurred on Friday, September 21st. The stock was acquired at an average price of $0.25 per share, with a total value of $50,000.00. Following the completion of the purchase, the director now directly owns 300,000 shares of the company’s stock, valued at approximately $75,000. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Chairman Marc Rubin bought 400,000 shares of the firm’s stock in a transaction that occurred on Friday, September 21st. The shares were purchased at an average cost of $0.25 per share, with a total value of $100,000.00. Following the purchase, the chairman now directly owns 556,317 shares of the company’s stock, valued at $139,079.25. The disclosure for this purchase can be found here. Insiders have purchased 900,000 shares of company stock valued at $225,000 in the last ninety days. Company insiders own 19.50% of the company’s stock.

An institutional investor recently bought a new position in Titan Pharmaceuticals stock. Perkins Capital Management Inc. bought a new stake in shares of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,200,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $249,000. Perkins Capital Management Inc. owned approximately 5.66% of Titan Pharmaceuticals as of its most recent SEC filing. 12.17% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/11/10/titan-pharmaceuticals-inc-ttnp-short-interest-update.html.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment.

Featured Story: Balanced Fund

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply